Abbreviations
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AP-1

:   Activator Protein 1

EMT

:   Epithelial-to-mesenchymal transition

EMT-TF

:   Epithelial-to-mesenchymal transition transcription factor

Fra-1

:   Fos-related antigen 1

GEMMs

:   Genetically engineered mouse models

TF

:   transcription factor

TGFβ

:   Transforming growth factor β

Zeb1

:   Zinc finger E-box binding homeobox 1

Zeb2

:   Zinc finger E-box binding homeobox 2.
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Epithelial-to-mesenchymal transition (EMT) is a complex biological program occurring in physiological and pathological conditions.[@cit0001] The acquisition of a mesenchymal state by cancer cells is associated with loss of epithelial features, decreased cell adhesion and increased migration and invasion, which together are crucial for metastasis.

Down-regulation of the adherens junction protein E-cadherin is a hallmark of EMT. E-cadherin expression and epithelial plasticity are regulated by a number of molecular signaling pathways and regulators operating within dynamic circuits. Transcription factors (TFs) of the Snail, Twist and Zinc finger E-box binding homeobox (Zeb) families (collectively EMT-TFs) repress E-cadherin transcription and modulate additional epithelial and mesenchymal genes. EMT-TFs are controlled by growth factors such as Transforming growth factor β (TGFβ) and microRNAs, but also by a number of TFs.[@cit0001]

Fos-related antigen 1 (Fra-1) dimerize with Jun proteins to form the Activator Protein 1 (AP-1) transcription factor complex. Several studies, using human tumor material and cell lines correlated FRA-1 expression with malignancy. Compelling evidence implicates FRA-1 in EMT of human breast cancer cells and reports have connected FRA-1 as a dimer with c-JUN, with the EMT-TFs *SNAI*2/SLUG, ZEB1 and ZEB2.[@cit0002]

In our recent publication,[@cit0005] we set out to define how Fra-1 contributes to EMT and assess the evolutionary conservation of EMT-TF regulation by Fra-1. We used the EpH4 murine non-tumourigenic mammary epithelial cells, which display a well documented phenotypic plasticity in response to oncogenes or growth factors. Ectopic expression of Fra-1 in EpH4 cells (EpFra1) was sufficient to trigger a proliferative, mesenchymal and invasive phenotype. Importantly, EpFra1 cells formed tumors in orthotopic and lung colonisation assays. Mechanistically, Fra-1 induced critical changes in the mRNA and protein expression of *Tgfb1* and 2 EMT-TFs: *Zeb1* and *Zeb2*. Gene expression profiling confirmed that Fra-1 induced gene expression programmes characteristic of EMT, transformation and invasiveness. In addition, we identified a Zeb1/2 molecular signature in Fra-1-expressing cells, which was further validated by mRNA and protein analyses. Moreover, and in line with the recently emerging relationship between EMT, stemness and Fra-1/AP-1 in breast cancer,[@cit0004] EpFra1 cells displayed a mammary stem cell signature. Finally, distinct changes in the expression of genes such as *Secreted acidic cysteine rich glycoprotein* (*Sparc*), *Matrix metallopeptidase 2* (*Mmp2)*, *Interleukin 13 receptor,*α*2* (*Il13ra2)*, and *Angiopoietin-like 4 (Angptl4)*, previously associated with lung tropism of human breast cancer cells,[@cit0006] were measured.

We next determined how Fra-1 modulates *Tgfb1* and *Zeb1/2* expression and how these genes contribute to the phenotypes observed in EpFra1 cells. Chromatin immunoprecipitation demonstrated that Fra-1 bound the mouse *Tgfb1* promoter. However, inhibiting TGFβ signaling in EpFra1 cells only modestly increased epithelial marker expression, indicating that TGFβ signaling contributes, but is likely not essential for Fra-1-induced EMT.

We next tested whether Fra-1 directly regulates Zeb1 and Zeb2 transcription, focusing on genomic sequences with potential AP-1-binding elements conserved in the human genes. Fra-1 bound the murine *Zeb2* promoter and we identified 3 novel AP-1 sites responsible for the activation of a *Zeb2* promoter reporter by Fra-1. This demonstrates for the first time, a direct transcriptional regulation of Zeb2 by an AP-1 TF. In addition, Fra-1 bound a region in the mouse *Zeb1* gene homologous to the region of the human *ZEB1* gene recently implicated in breast cancer cell plasticity.[@cit0007] Whether FRA-1 regulates *ZEB1* expression in breast cancer cells by altering the epigenetic landscape[@cit0002] is an attractive possibility that certainly merits future investigation.

Consistent with the situation in human cells, RNA interference demonstrated that the EMT phenotype triggered by Fra-1 was largely dependent on increased Zeb1/2. Reducing the expression of Zeb1 and Zeb2, and to a lesser extent Zeb2 in EpFra1 cells, restored the expression of Zeb target genes including E-cadherin and reduced migration and invasion *in vitro*. In addition, EpFra1 cells with Zeb1/2 knock-down displayed decreased orthotopic tumourigenesis. However, most strikingly these cells could still colonize the lungs, with a notable fraction of the tumors retaining E-cadherin expression. Thus Zeb1 and Zeb2 are critical mediators of E-cadherin downregulation and EMT downstream of Fra-1, while other Fra-1 targets, independent of Zeb1/2, likely sustain the proliferative, tumourigenic and distant organ colonisation capacity of EpFra1 cells ([**Fig. 1**](#f0001){ref-type="fig"}). Figure 1.Fos-related antigen 1 (Fra-1) functions in mammary tumourigenesis and metastasis. Fra-1 increases Zinc finger E-box binding homeobox (Zeb) 1, Zeb2 and TGFβ expression, largely through direct promoter binding. Increased Zeb1/2 and Transforming growth factor β (TGFβ) signaling decreases E-cadherin, ultimately leading to epithelial-to-mesenchymal transition (EMT) and the acquisition of migratory and invasive properties. In addition, Fra-1 increases proliferation, distant organ colonisation and stemness of mammary cells, partly in an EMT/Zeb-independent manner.

Genetically engineered mouse models (GEMMs) are of great potential for therapy development, in particular to tackle the metastatic phase of cancer in a non-compromised immune environment. Our work provides novel insights how Fra-1/AP-1 is connected to the complex network of EMT modulators and demonstrates that the mechanistic basis of Fra-1 contribution to EMT is largely conserved in mouse cells. The next step is to evaluate our findings in GEMMs and assess how manipulating Fra-1 expression in the tumor or its environment, would affect mammary tumor development *in vivo*. Transgenic mice broadly expressing Fra-1 develop osteosclerosis and generalized fibrosis, which precludes mammary tumor analyses.[@cit0008] We recently generated switchable, cell type-specific, gain of function alleles for Fra-1 and for the c-Jun~῀~Fra-1 dimer,[@cit0009] which should allow to carefully assess the phenotypic consequences of increased Fra-1 expression in the mammary epithelium of wild-type or breast cancer-prone mice, such as the MMTV-PyMT GEMM. Conversely, the therapeutic potential of inactivating Fra-1 along the different stages of breast cancer progression could be assessed by inducible gene inactivation in specific cells of the mammary gland, a strategy we successfully applied in the past to liver cancer.[@cit0010] The results from such studies will likely provide further valuable insights into how to best inhibit metastatic tumor progression and help improve the clinical outcome of cancer patients.
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